Abstract
The role of adjuvant therapy in breast-conserving treatment was studied in 360 cancer patients (reproductive, aged < or = 55 yrs, and postmenopausal, aged > 55 yrs) with T1-2N0M0 tumors under 2.5 cm (1985-1996). Mortality rates fell by 17% in postmenopausal patients who received adjuvant therapy (tamoxifen) and by 34%--in the reproductive group after polychemotherapy (CMF) and 36%--after hormonal therapy (tamoxifen).
Publication types
-
Clinical Trial
-
English Abstract
-
Randomized Controlled Trial
MeSH terms
-
Antineoplastic Agents, Hormonal / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / mortality
-
Breast Neoplasms / pathology
-
Breast Neoplasms / surgery
-
Chemotherapy, Adjuvant
-
Disease-Free Survival
-
Female
-
Humans
-
Mastectomy, Segmental*
-
Middle Aged
-
Neoplasm Staging
-
Postmenopause
-
Premenopause
-
Survival Analysis
-
Tamoxifen / administration & dosage
-
Treatment Outcome
Substances
-
Antineoplastic Agents, Hormonal
-
Tamoxifen